Analysts Set Artivion, Inc. (NYSE:AORT) Target Price at $31.40

Shares of Artivion, Inc. (NYSE:AORT - Get Free Report) have been given a consensus recommendation of "Buy" by the six analysts that are currently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $31.40.

Several research analysts recently commented on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a research note on Tuesday, May 6th. Needham & Company LLC reissued a "buy" rating and issued a $32.00 price objective on shares of Artivion in a research report on Tuesday, May 6th. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus decreased their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 25th.

Insider Activity at Artivion

In other news, Director Anthony B. Semedo sold 2,600 shares of the company's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $28.47, for a total value of $74,022.00. Following the completion of the sale, the director now owns 33,059 shares of the company's stock, valued at approximately $941,189.73. This represents a 7.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jean F. Holloway sold 18,020 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $425,452.20. Following the transaction, the senior vice president now owns 197,184 shares in the company, valued at approximately $4,655,514.24. This represents a 8.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,942 shares of company stock worth $1,704,794 over the last three months. 7.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Artivion

A number of large investors have recently bought and sold shares of AORT. Diker Management LLC bought a new stake in Artivion during the 1st quarter valued at $369,000. Fred Alger Management LLC purchased a new stake in shares of Artivion during the 1st quarter worth $2,969,000. Parkman Healthcare Partners LLC bought a new stake in Artivion during the first quarter valued at about $2,744,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company's stock valued at $580,000 after purchasing an additional 1,032 shares in the last quarter. Finally, Bridger Management LLC purchased a new position in Artivion in the first quarter valued at about $1,580,000. Institutional investors own 86.37% of the company's stock.

Artivion Trading Up 0.6%

Shares of Artivion stock traded up $0.18 on Friday, reaching $28.63. The company had a trading volume of 281,558 shares, compared to its average volume of 332,513. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -1,431.50 and a beta of 1.54. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The firm's 50-day moving average price is $25.87 and its two-hundred day moving average price is $27.42. Artivion has a 1 year low of $21.97 and a 1 year high of $32.33.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The firm had revenue of $98.98 million for the quarter, compared to analysts' expectations of $94.81 million. As a group, research analysts predict that Artivion will post 0.37 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.